FDA, Penn make it personal
FDA and the University of Pennsylvania sign a five-year memorandum of understanding aimed at advancing drug/device co-development, companion diagnostics, translational medicine and new clinical trial models, among other goals, FDA announces Sept. 9. The two hope to develop safer, more effective drugs, devices, and biologics targeted at individuals rather than broad populations, a growing focus for FDA and for industry. The agreement also facilitates exchanges between FDA personnel and Penn students and faculty, which could help FDA recruitment efforts
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.